<DOC>
	<DOCNO>NCT02529956</DOCNO>
	<brief_summary>To evaluate safety UCB4940 administer iv infusion single ascend dose subject mild moderate plaque psoriasis .</brief_summary>
	<brief_title>A Study Assess Safety , Pharmacokinetics Pharmacodynamics UCB4940 Patients With Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Inclusion criterion : Subject male female , age ≥ 18 year ≤ 70 year Screening . Female subject must either postmenopausal ( least 1 year ) , permanently sterilize , childbearing potential , must willing use least 2 effective method contraception , include barrier method study period . Effective method contraception method birth control , result low failure rate use consistently correctly , implant , injectables , oral contraceptive , progesteronereleasing intrauterine system TCu 380A intrauterine device , complete sexual abstinence , vasectomized partner . Male subject partner childbearing potential must willing use condom sexually active . Both male female subject must use mentioned contraception 20 week administration study drug ( anticipated 5 halflives ) Subject confirm diagnosis mild moderate plaquetype psoriasis least 6 month involve ≤ 5 % body surface area ( BSA ) ( exclude scalp ) Subject body mass index ≤ 35 kg/m^2 Screening Subject minimum 2 psoriatic lesion least 1 plaque site suitable biopsy Female subject pregnant , plan become pregnant study , lactate , sexually active childbearing potential use medically accept birth control method Subject receive systemic nonbiologic psoriasis therapy ( methotrexate [ MTX ] , steroid , cyclophosphamide ) psoralen plus ultraviolet A ( PUVA ) /ultraviolet A ( UVA ) phototherapy within 4 week prior Screening Subject receive treatment biologic agent within 12 month prior study Subject receive live attenuate vaccination within 6 week prior Screening intend vaccination course study Subject receive investigational drug experimental procedure within 90 day 5 halflives , whichever longer , prior IMP administration Subject require treatment nonsteroidal antiinflammatory drug study period . Paracetamol permit use antipyretic and/or analgesic Subject active infection ( eg , sepsis , pneumonia , abscess ) serious infection ( result hospitalization require parenteral antibiotic treatment ) within 6 week prior IMP administration . When doubt , Investigator confer UCB Study Physician Subject history positive tuberculosis ( TB ) test evidence possible TB latent TB infection Screening attribute prior Bacillus CalmetteGuérin inoculation Subject renal liver impairment , define : For woman , serum creatinine level ≥ 125 μmol/L ; men , ≥ 135 μmol/L , ALT aspartate aminotransferase ≥ 2x ULN , Alkaline phosphatase bilirubin &gt; 1.5x ULN ( isolated bilirubin &gt; 1.5x ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) Subject active neoplastic disease history neoplastic disease within 5 year Screening ( except basal squamous cell carcinoma skin carcinoma situ definitively treat standard care )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>UCB4940</keyword>
</DOC>